Defeat Duchenne Canadian Conference 2021: Addressing Duchenne muscular dystrophy (DMD) Standards of Care in Canada
The Neuromuscular Disease Network for Canada (NMD4C) in partnership with Jesse’s Journey and Muscular Dystrophy Canada (MDC), is proud to announce the inaugural Defeat Duchenne Canadian Conference, the first national summit solely focused on Duchenne muscular dystrophy (DMD) for health care providers across Canada.
The theme for this year’s virtual event is DMD standards of care (SoC). This three-part conference will bring together subject matter experts from pediatric and adult care for a comprehensive overview of the Canadian adaptation to the international DMD care considerations published in 2018.
What: Defeat Duchenne Canadian Conference: Addressing DMD Standards of Care in Canada
Who should attend: Multidisciplinary health care professionals involved in the care of DMD patients.
Session 1 (of 3): The first session will focus on the following DMD topics:
• Endocrinology management and bone health
• Cardiac management
• Pulmonary management
Friday, June 18, and Saturday, June 19, 2021, from 11 a.m. – 2 p.m. EDT each day. The second and third sessions will take place in September and December – stay tuned for registration later in the year.
Where: Online (Whova + Zoom)
We hope you and your team will join Jesse’s Journey and our partners as we build the future for Duchenne muscular dystrophy in Canada through research and collaboration.
First session of the three-part virtual conference starts June 18 and 19, 2021. Learn more about the sessions and speakers, and register today: www.dmdcanadianconference.com
Read next...
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.
New Best Practice Recommendations for SBMA Care in Canada
Congratulations to Dr. Kerri Schellenberg, the team of Canadian experts, NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!
Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting
On September 11, NMD4C hosted its 2025 Annual Meeting in Ottawa, bringing together clinicians, researchers, trainees, and partners for a full day of collaboration, strategic dialogue, and community-building.
NMD4C Hosts Inaugural Clinical Summer School to Empower Canada’s Future Neuromuscular Leaders
On September 10–11, NMD4C hosted its inaugural Clinical Summer School in Ottawa, bringing together 19 neuromuscular clinical fellows from across Canada for two days of hands-on training, mentorship, and networking. Led by national experts and co-chaired by Drs. Gordon Jewitt and Marianne Nury, the program complemented NMD4C’s accredited lecture series and fostered peer connection through dedicated community-building sessions.
2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!
Apply Or Share this opportunity with the trainees in your network — Deadline: October 14, 2025. Hosted by Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC)
Announcing the 2026 Neuromuscular Clinical Fellowship Award Recipients
We are excited to share that the 2026 Neuromuscular Clinical Fellowship Awards have been awarded! These fellowships strengthen clinical training in neuromuscular medicine and help prepare the next generation of specialists who will advance neuromuscular care across Canada.